Last reviewed · How we verify

AdCLD-CoV19-1 OMI

Cellid Co., Ltd. · Phase 3 active Biologic

AdCLD-CoV19-1 OMI is a Viral vector vaccine Biologic drug developed by Cellid Co., Ltd.. It is currently in Phase 3 development for COVID-19 prevention (Omicron variant).

AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens.

AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens. Used for COVID-19 prevention (Omicron variant).

At a glance

Generic nameAdCLD-CoV19-1 OMI
SponsorCellid Co., Ltd.
Drug classViral vector vaccine
TargetSARS-CoV-2 Omicron variant spike protein
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

This vaccine uses a replication-deficient adenoviral vector to deliver genetic material encoding Omicron variant spike protein or related antigens, triggering both cellular and humoral immune responses. The adenoviral platform is designed to stimulate T-cell and B-cell immunity to provide protection against COVID-19 infection and severe disease caused by Omicron and related variants.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AdCLD-CoV19-1 OMI

What is AdCLD-CoV19-1 OMI?

AdCLD-CoV19-1 OMI is a Viral vector vaccine drug developed by Cellid Co., Ltd., indicated for COVID-19 prevention (Omicron variant).

How does AdCLD-CoV19-1 OMI work?

AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens.

What is AdCLD-CoV19-1 OMI used for?

AdCLD-CoV19-1 OMI is indicated for COVID-19 prevention (Omicron variant).

Who makes AdCLD-CoV19-1 OMI?

AdCLD-CoV19-1 OMI is developed by Cellid Co., Ltd. (see full Cellid Co., Ltd. pipeline at /company/cellid-co-ltd).

What drug class is AdCLD-CoV19-1 OMI in?

AdCLD-CoV19-1 OMI belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is AdCLD-CoV19-1 OMI in?

AdCLD-CoV19-1 OMI is in Phase 3.

What are the side effects of AdCLD-CoV19-1 OMI?

Common side effects of AdCLD-CoV19-1 OMI include Injection site pain or erythema, Fever, Fatigue, Myalgia.

What does AdCLD-CoV19-1 OMI target?

AdCLD-CoV19-1 OMI targets SARS-CoV-2 Omicron variant spike protein and is a Viral vector vaccine.

Related